Michigan GLP-1 Med Spa Compliance 2026

The gap between a Michigan GLP-1 program that survives a complaint and one that does not is rarely the medicine. It is almost always a document that did not exist or was written after the fact — the evaluation nobody charted, the delegation nobody papered, the vial nobody can trace to a licensed pharmacy.

That follows from how Michigan regulates. There is no medical spa act, no clinic registration, and no inspection cycle to catch a thin file before a patient complains. Authority comes from Public Health Code provisions administered by LARA, with scope decided by the Michigan Board of Medicine and Board of Nursing, sourcing by the Board of Pharmacy, and compounding by the FDA. For the national framework, our complete GLP-1 med spa compliance guide covers the baseline, and the 503A versus 503B sourcing guide goes deeper on where the product comes from.

Michigan Regulates GLP-1 Weight Loss Through Delegation, Not a Clinic Licence

Operators arriving from states with a medical spa act look for the Michigan equivalent and conclude, wrongly, that a permissive framework is a light one. Michigan asks the same questions — it simply never gathered them in one place, and never built a front-end filter to catch a bad answer.

MCL 333.16215 and the supervision test that makes delegation real

Michigan's general delegation provision does the work an aesthetics-specific rule does elsewhere. Under MCL 333.16215, a licensee may delegate selected acts, tasks, or functions to a licensed or unlicensed individual otherwise qualified by education, training, or experience — provided the act sits within the delegator's own scope and is performed under supervision. The section also sets the ceiling: no delegation where the act requires the level of education, skill, and judgment the Code demands of the licensee.

MCL 333.16109 then defines supervision conjunctively — continuous availability of direct communication, a licensed professional available on a regularly scheduled basis to review the supervised individual's practice, and predetermined procedures and drug protocol. Physical presence is not required, which is why Michigan tolerates off-site medical direction; a phone number alone is not supervision either, which is why so many files fail on the second and third limbs. Our guide to who can inject Botox in Michigan works through it in the injectables context.

What changed for Michigan weight loss programs going into 2026

Two 2026 developments shape the environment rather than the rules. Effective January 1, 2026, Michigan Medicaid sharply restricted coverage of GLP-1 agents prescribed solely for obesity — Wegovy, Zepbound, Saxenda, and generic liraglutide — limiting approval to patients who are morbidly obese, have failed other clinically appropriate interventions and preferred agents, and are using the drug to avert bariatric surgery. Coverage of agents approved for type 2 diabetes did not change.

That is a coverage decision, not a scope decision, and it pushes volume toward the cash-pay programs this guide is about just as federal compounding policy tightened. Separately, Public Act 6 of 2026, signed March 26, 2026, re-enacted Michigan's participation in the Interstate Medical Licensure Compact without a sunset. For the wider comparison, the med spa regulations by state reference sets the comparison out.

Who Can Prescribe GLP-1 Medications in Michigan

Everything downstream depends on a lawful order, and Michigan is unusually clear here. The clarity turns on a fact many operators overlook: GLP-1 receptor agonists are not controlled substances, which puts them in the most permissive category of Michigan prescribing authority.

Michigan-licensed physicians

Verdict: yes, on their own authority. A physician licensed by the Michigan Board of Medicine or the Board of Osteopathic Medicine and Surgery may evaluate the patient, select the agent, set the titration schedule, and order it — and is the origin of most delegations in the building, so the protocol and the delegation file are their responsibility whether or not they see patients in person.

APRNs and Michigan's independent nonscheduled prescribing authority

Verdict: yes, in their own name, with no physician signature on the order. Michigan recognises the advanced practice registered nurse — a registered professional nurse granted specialty certification by the Board of Nursing as a nurse practitioner, nurse midwife, or clinical nurse specialist. Under MCL 333.17211a, effective April 9, 2017, an APRN may prescribe nonscheduled prescription drugs with only the APRN's name recorded on the order.

Semaglutide, tirzepatide, and liraglutide are nonscheduled, which places the whole category inside independent APRN prescribing authority — a materially different answer from a controlled weight loss drug, where both the APRN's and the physician's name must appear. Add phentermine later and the staffing model changes underneath you.

Be precise about what this does not mean. The American Association of Nurse Practitioners still classifies Michigan as a reduced practice state, so treat any source calling it full practice authority as unreliable. The classification describes the whole scope; the nonscheduled carve-out is what a GLP-1 program runs on.

Physician assistants under a practice agreement

Verdict: yes, within the terms of the agreement. Since 2016 PA 379, Michigan PA practice is the practice of medicine with a participating physician under a practice agreement rather than by delegation. A PA may evaluate a weight loss patient, order the drug, and manage titration. The agreement must address communication, availability, and decision making; designate an alternative physician; carry both signatures; and permit termination on at least 30 days' written notice.

Because the PA practises under the agreement rather than by delegation, silence in it is a genuine problem: an agreement drafted for primary care that says nothing about pharmacological weight management is thin cover for a med spa GLP-1 line.

Who cannot prescribe, in any configuration

RNs, LPNs, medical assistants, estheticians, health coaches, dietitians, and unlicensed staff cannot prescribe a GLP-1 in Michigan. Neither can a corporate entity, a management company, or an app. A physician-authored protocol does not become an order, and a standing order covering every patient who books is the recurring Michigan failure: deciding that this patient gets this drug at this dose is the judgment the delegation ceiling reserves to the licensee.

Who Can Administer a GLP-1 Injection in Michigan

Administration is a separate question from prescribing, and Michigan answers it through delegation rather than a list — more permissive on paper, more demanding in evidence.

Registered nurses

Verdict: yes, on a valid patient-specific order. MCL 333.17201 defines the practice of nursing as the systematic application of substantial specialised knowledge and skill to the care, treatment, counsel, and health teaching of individuals experiencing changes in normal health processes. Administering a prescribed drug sits inside that. Determining candidacy, choosing between molecules, and setting the titration ladder do not.

Board of Nursing rules also govern what an RN may hand further down. Only a registered nurse may delegate nursing acts, and one who does must confirm the task is within their own scope, assess the delegatee's qualifications, supervise and evaluate performance, and remediate where indicated. Letting a nurse informally hand injections to unlicensed staff usually breaches that rule and the physician's delegation file at once.

LPNs, medical assistants, and unlicensed staff

Verdict: possible under MCL 333.16215, and the riskiest configuration in the state. Michigan does not license medical assistants, so there is no scope to consult — only delegation. An LPN practises nursing based on less comprehensive knowledge and skill than an RN, under supervision. Both routes are open in principle, and both put the practice's defence into a training file that must be specific to GLP-1 administration: injection technique, the vial or pen system, dose verification, recognition of hypoglycaemia and severe gastrointestinal reactions, and what the delegatee is instructed to do rather than decide.

Patients who inject at home

Most Michigan GLP-1 patients inject themselves, so the teaching visit is the clinical encounter that matters and should be charted as one: who taught, what vial or pen system, what dose in milligrams, and what the patient demonstrated back. The FDA has flagged dosing errors with compounded semaglutide where instructions were given in "units" rather than milligrams, with patients drawing five to twenty times the intended dose.

The Good-Faith Exam and Telehealth Prescribing in Michigan

Michigan has no statute or rule using the phrase "good faith exam," and the absence is routinely misread as permission to skip it. The requirement is real; it arrives through prescribing standards rather than a dedicated section.

What a Michigan prescriber must establish

Before a first dose, a Michigan prescriber should be able to show from the chart alone that they established the patient's identity and history, took baseline measurements, considered why a GLP-1 is indicated for this person, screened the contraindications the labelling names, discussed alternatives and adverse effects, obtained consent, and issued a specific order. A prescriber who never interacted with the patient has not done this, and neither has one who signed off a batch of intake forms.

Michigan permits telehealth prescribing, and holds it to the same standard

Michigan imposes no in-person examination requirement for a nonscheduled drug. MCL 333.16285 permits a health professional providing a telehealth service to prescribe where they are a prescriber acting within scope, with extra conditions only for controlled drugs. MCL 333.16284 requires consent before a telehealth service is provided, with proof stored in the record consistent with MCL 333.16213. Board rules add that telehealth carries the same standard of care as an in-person service — so a remote GLP-1 program needs stronger documentation, not weaker.

Michigan's electronic prescribing mandate

A Michigan-specific trap sits next to the telehealth rule. Under MCL 333.17754a, prescribers must electronically transmit prescriptions — controlled and noncontrolled alike — directly to the pharmacy of the patient's choice unless a narrow exemption applies. "The pharmacy of the patient's choice" is a real phrase: a program routing every prescription to one affiliated compounder should be able to show the patient chose it. If you fax orders instead, identify the exemption rather than assuming the mandate covers only opioids.

Compounded Semaglutide and Tirzepatide: 503A, 503B, and Michigan Sourcing

This is where Michigan programs built during the shortage era are most exposed: the federal ground they stand on has been gone for over a year, and the marketing did not change with it.

The shortage era ended, and these are the dates that ended it

Mass compounding of GLP-1 copies was lawful because the drugs were on the FDA shortage list. That basis is withdrawn. The FDA determined the tirzepatide shortage resolved on December 19, 2024, with enforcement discretion ending February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B facilities. It removed semaglutide from the list on February 21, 2025, with discretion to April 22, 2025 and May 22, 2025 respectively. Nothing in that timeline is Michigan-specific, which is why it catches Michigan practices.

What still qualifies as lawful 503A compounding

Section 503A did not disappear when the shortages resolved. It permits a state-licensed pharmacy or a physician to compound for an identified individual patient on a valid prescription regardless of shortage status. The constraint is the essentially-a-copy limitation: compounding what is effectively a commercially available approved product is not permitted absent a documented clinical difference for that patient. An allergy to an excipient can support it; "cheaper" and "our standard protocol" cannot, and a justification template identical for every patient is not a clinical determination.

503A versus 503B, and what each can actually supply

The distinction decides what may sit in your fridge. A 503A pharmacy compounds against individual prescriptions and cannot supply office stock for future unidentified patients. A 503B outsourcing facility registers with the FDA, operates under CGMP, and may produce without patient-specific prescriptions — which is what makes office stock possible for other drugs. For semaglutide and tirzepatide that route closed in 2025, so bulk compounded GLP-1 vials held for walk-in use are a sourcing problem whoever supplied them.

Michigan's pharmacy licensing layer on top of the federal rules

Michigan adds a condition federal law does not. Under MCL 333.17748, a pharmacy must be licensed under Michigan's pharmacy practice laws to do business in this state whether or not it is located in Michigan, subject to the qualified-pharmacy provisions at MCL 333.17748e — so an out-of-state compounder shipping semaglutide to a Michigan patient is doing business here. Ask for its Michigan licence number, verify it against LARA's lookup, and keep a dated copy in the sourcing file. Vials sold as "research use only" or as peptides from a non-pharmacy supplier fail this test outright: no pharmacy licence, no compounding standards, no verified potency.

The April 2026 bulks proposal — genuinely unsettled

One live federal question should be tracked, not guessed at. On April 30, 2026, the FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list, with a comment period closing June 29, 2026. As of this writing it is not finalised, and commentary predicting an outcome or date is prediction rather than law.

Dispensing GLP-1s In-House: Michigan's Drug Control Licence

Many Michigan weight loss programs hand the patient a vial or pen at the visit rather than sending a prescription to a pharmacy. That is a licensing act in Michigan — the requirement out-of-state operators have most often never heard of.

What MCL 333.17745 requires

A prescriber who wishes to dispense prescription drugs must obtain from the board a drug control licence for each location at which those drugs are stored and dispensed. The exceptions are narrow: hospital emergency settings licensed under article 17, or dispensing only complimentary starter doses. A med spa handing out GLP-1 vials fits neither. Writing an order a pharmacy fills is prescribing; storing product on your premises and transferring it is dispensing, and that triggers the licence plus storage, labelling, and recordkeeping duties.

What a dispensing prescriber must record

Michigan also limits who may receive the product. A dispensing prescriber shall dispense only to their own patients, and shall include in the chart a complete record — drug names, dosages, and quantities — of all drugs dispensed directly by the prescriber or indirectly under their delegatory authority.

Read that last clause carefully, because it reaches the front desk. If an assistant hands the vial over, the drug was dispensed under the prescriber's delegatory authority and the prescriber owns the record. A dispensing log kept in a spreadsheet apart from the chart does not satisfy a requirement written around the clinical record.

Complimentary starter doses are not a workaround

The exception is narrower than its name suggests. A complimentary starter dose is a drug provided to the prescriber free of charge by a manufacturer or distributor and dispensed free of charge to their patients, and it still carries storage, recordkeeping, and labelling duties. Compounded vials a practice buys and supplies inside a paid program are not starter doses in any sense the statute recognises.

Screening, Eligibility, and Contraindications in a Michigan Protocol

Michigan sets no eligibility criteria for cash-pay weight management, so your written protocol is the standard you will be measured against. A reviewer will read your own protocol back to you and ask whether the chart matches it.

Eligibility criteria a Michigan protocol should state

Write down in advance what qualifies a patient: the BMI thresholds you use and whether a lower one applies with a weight-related comorbidity, the age floor, the lifestyle intervention you expect alongside pharmacotherapy, and what disqualifies a candidate outright. Then follow it — inconsistency across charts turns one complaint into a pattern finding.

Contraindications a Michigan protocol must screen

Screening should be a documented step with an answer in the chart, not a conversation someone remembers. The class labelling and its boxed warning drive the core list, and a Michigan protocol should require a recorded answer on each of the following:

• Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
• Known hypersensitivity to the active molecule or to any excipient in the specific product being supplied.
• Pregnancy, planned pregnancy, or breastfeeding, with contraception counselling documented.
• History of pancreatitis, symptomatic gallbladder disease, or severe gastrointestinal disease including gastroparesis.
• Diabetic retinopathy, and insulin or sulfonylurea use raising hypoglycaemia risk.
• Severe renal or hepatic impairment, and any medication with a narrow therapeutic index affected by delayed gastric emptying.
• History of an eating disorder, and any suicidal ideation or significant psychiatric history.
• Planned surgery or sedation, given anaesthesia guidance on retained gastric contents.

What the screening note has to prove

The chart should show each item was asked and answered, not merely that a form existed; a negative is a finding and should be recorded as one. Where a relative contraindication is present and the prescriber proceeds anyway, the reasoning belongs in the note — that entry converts a later adverse outcome from a scope question into a clinical judgment question.

Monitoring and Follow-Up a Michigan Program Must Deliver

Michigan prescribes no follow-up interval, so the interval in your protocol becomes the standard. Programs that sell twelve weeks of medication at intake and see the patient once are hard to defend in a state that measures conduct against prevailing practice.

What to capture before the first dose

Capture and chart the starting point: weight, height, BMI, blood pressure and heart rate, and the baseline laboratory panel your protocol specifies — commonly HbA1c or fasting glucose, a metabolic panel with renal and hepatic function, and a lipid panel. Record the starting dose in milligrams, the product and its source, and the titration schedule. Without a baseline there is no way to show the program monitored anything.

Titration, and who decides each increase

Dose escalation is where most adverse events arrive, and the phase remote-heavy programs cover most thinly. Your protocol should state the escalation interval, the criteria for holding or reducing, and the maximum dose. Each escalation should be a documented prescriber decision — weight change, tolerance, side effects, adherence — not a step a fulfilment system takes on a calendar.

Adverse events, dosing errors, and escalation

Give staff a written escalation threshold rather than an instinct. Persistent vomiting, severe abdominal pain radiating to the back, signs of gallbladder disease, hypoglycaemia in a patient on insulin or a sulfonylurea, and new or worsening mood symptoms each need a defined route to the prescriber and a documented response. Add a dose-verification step: confirm at every visit that the patient can state their dose in milligrams and show how they measure it.

Recordkeeping a Michigan GLP-1 Program Must Keep

Because Michigan has no inspection cycle, nobody reviews your files until something has gone wrong — at which point the files are the entire case. Compliance here is retrospective, which changes what is worth keeping and when it must have been created.

The patient chart

Per patient, the chart should carry the prescriber's evaluation and who performed it; the screening answers including the boxed-warning items; baseline measurements and labs; consent naming the product, its risks, and its regulatory status; telehealth consent under MCL 333.16284 where the encounter was remote; the order with drug, strength, dose in milligrams, route, and titration plan; who administered or taught self-injection; each follow-up with weight, tolerance, and the reasoning behind any dose change; and any adverse event.

The sourcing file

Keep a chain running from the vial in the room back to a licensed source: the pharmacy's name and its Michigan pharmacy licence, its 503A or 503B status, invoices, lot numbers and expiry dates matched to the patients who received them, refrigeration logs, and beyond-use dating. Keep each patient-specific compounding justification in that patient's chart rather than as a program-wide policy, and if you dispense on site, file the drug control licence and MCL 333.17745 records alongside.

The delegation and protocol file

Then keep the documents proving the program was lawfully constituted: the delegating licensee's identity and licence number; the specific acts delegated to each individual, named narrowly enough that a reviewer can tell what was authorised; dated competency assessments signed by the delegator; the predetermined procedures and drug protocol required by MCL 333.16109, dated before the first treatment it governs; records of the scheduled practice review; and current licence verifications.

Advertising a Michigan Weight Loss Program

Advertising is an independent route to discipline in Michigan and does not require a harmed patient. It is also the part of the program a marketing agency usually controls without reading the statute.

What MCL 333.16221 makes actionable

MCL 333.16221 lists false or misleading advertising as grounds for discipline, and separately lists misrepresenting the type, quality, appropriateness, or skill of services. Sanctions under MCL 333.16226 run from fines and probation through suspension to revocation, and a competitor or former employee reporting a claim is enough to start it.

Two claims recur in Michigan weight loss marketing and both are exposed. Describing compounded semaglutide as "FDA-approved" is false — compounded drugs are not approved, and the brand names belong to products you are not supplying. And promoting a trial outcome as typical, when it reflects a particular dose alongside lifestyle intervention in a selected population, misrepresents what your program delivers.

Michigan's consumer protection layer

Beyond the licensing boards sit the Michigan Consumer Protection Act and, federally, the FTC's expectation of competent and reliable scientific substantiation for health claims. These reach the entity as well as the licensee — a physician can be disciplined for the advertising while the business is pursued for the same copy.

Before-and-after photos, testimonials, and brand names

Keep consent for every photograph, specific to the use. Represent results honestly, including the timeframe, the dose, and whether the patient was also on a supervised diet and exercise programme. Do not use another manufacturer's brand name for a compounded product — the name invites a regulatory complaint and a trademark one. Be careful how staff are described too, since holding someone out as practising a profession they are not licensed in has consequences under MCL 333.16294.

What Gets a Michigan Practice Disciplined

Michigan has no med spa inspectorate, so enforcement is complaint-driven and arrives through LARA and the disciplinary subcommittees. The trigger is usually an adverse outcome, a departing employee, or a competitor — and the investigation is almost always about the file rather than the incident.

Unlicensed practice and negligent delegation

Two provisions carry most of the risk. Practising, or holding oneself out as practising, a health profession without a licence is a felony under MCL 333.16294, and published descriptions of the penalty range vary enough to confirm the text with counsel. On the supervising side, MCL 333.16221 makes negligence or failure to exercise due care actionable, expressly including negligent delegation to or supervision of employees or other individuals, whether or not injury results.

Discipline across three boards at once

A single GLP-1 complaint can open on three fronts. The Board of Medicine or the Board of Osteopathic Medicine and Surgery examines the prescriber's evaluation and delegation. The Board of Nursing examines the RN or APRN, including whether a nurse administered without a valid order. The Board of Pharmacy examines the product: where it came from, whether the supplying pharmacy holds a Michigan licence, and whether the practice dispensed without a drug control licence.

Civil liability and the insurance gap

Alongside licensure and criminal exposure sits civil liability, plus an insurance problem that lands at the worst moment: professional liability policies commonly exclude acts outside the insured's scope. In a delegation state, scope is established by the delegation file rather than the licence on the wall, so a defective file can be both the reason a claim exists and the reason it is uncovered.

Summary: Building a Compliant Michigan GLP-1 Program

Put the four bodies of law together and a defensible Michigan weight loss program has a recognisable shape.

1. Name a lawful prescriber — a Michigan-licensed physician, an APRN prescribing in their own name under MCL 333.17211a, or a PA under a practice agreement covering weight management.
2. Require a patient-specific evaluation every time, in person or by telehealth, with consent documented under MCL 333.16284 and an order naming drug, strength, dose, route, and titration plan.
3. Delegate administration properly. Non-prescribers administer only under MCL 333.16215, with all three limbs of MCL 333.16109 satisfied and a dated GLP-1-specific competency file per delegatee.
4. Verify sourcing on both levels — whether the compounding is lawfully patient-specific, and whether the pharmacy holds a Michigan licence under MCL 333.17748.
5. Get a drug control licence before dispensing on site, as MCL 333.17745 requires, and record every drug name, dosage, and quantity in the chart.
6. Write the eligibility and screening protocol down, including the boxed-warning items, and chart an answer for each patient rather than relying on an unreviewed intake form.
7. Set and follow real monitoring intervals, with each dose escalation a documented prescriber decision and a written threshold for adverse events.
8. Audit the marketing against MCL 333.16221, removing FDA-approval claims for compounded product, brand names you do not supply, and unsubstantiated outcome promises.

If drafting the protocols, screening forms, consents, and monitoring schedules from scratch is not how you want to spend the next month, our library of ready-to-use med spa compliance SOPs covers the documentation behind every step above, and the Weight Loss Kit gathers the GLP-1-specific pieces in one place.

For more Michigan-specific guidance as this cluster grows, browse the Michigan med spa compliance hub.

This article is for informational purposes only and does not constitute legal or medical advice, and nothing here is a treatment recommendation. Michigan prescribing, delegation, pharmacy, and telehealth requirements are administered by LARA and its boards and change over time, and several points here — the expected depth of a pre-treatment evaluation, the boundary of patient-specific compounding justifications, and the outcome of the FDA's April 2026 503B bulks proposal — are genuinely unsettled. Confirm current requirements with LARA, the Michigan Board of Medicine, the Michigan Board of Nursing, and the Michigan Board of Pharmacy, and consult a Michigan healthcare attorney before building or changing a weight loss program.

Frequently Asked Questions